Company Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
| Country | United States |
| Founded | 1988 |
| IPO Date | Apr 2, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13,450 |
| CEO | Leonard Schleifer |
Contact Details
Address: 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 United States | |
| Phone | 914 847 7000 |
| Website | regeneron.com |
Stock Details
| Ticker Symbol | REGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000872589 |
| CUSIP Number | 75886F107 |
| ISIN Number | US75886F1075 |
| Employer ID | 13-3444607 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Co-Chairman |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer and Co-Chairman |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research |
| Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations and Product Supply |
| Christopher R. Fenimore CPA | Senior Vice President of Finance and Chief Financial Officer |
| Patrice Gilooly | Senior Vice President of Quality Assurance and Operations |
| Bob McCowan | Senior Vice President of IT and Chief Information Officer |
| Ryan Crowe | Senior Vice President of Investor Relations and Strategic Analysis |
| Joseph J. LaRosa J.D. | Executive Vice President, General Counsel and Secretary |
| Melissa Lozner | Senior Vice President and Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | 144 | Filing |
| Oct 31, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 144 | Filing |
| Sep 11, 2024 | UPLOAD | Filing |
| Sep 3, 2024 | 144 | Filing |
| Aug 28, 2024 | 144 | Filing |
| Aug 15, 2024 | 144 | Filing |